The Problem: Why 90% of Drug Candidates Fail
Drug development is broken. It takes 10-15 years and costs $2.6 billion to bring a single drug to market, with a staggering 90% failure rate in clinical trials. At the heart of this crisis lies a fundamental modeling limitation: the industry relies on classical survival analysis and PK/PD modeling using simple linear models fitted on sub-population data. These models — Cox hazard models, mixed-effects approaches — use a limited number of known covariates and have zero ability to discover new variable relationships.
The consequence is devastating for precision therapeutics. Population-level averages cannot explain why Patient A responds to a drug while Patient B does not. In an era demanding individualized treatment decisions, these tools are fundamentally inadequate. Meanwhile, "tech-bio" startups applying cutting-edge AI to historical post-trial data have yet to produce a broad breakthrough — because the data was never designed for AI development in the first place.
The Solution: AI-Designed Data Collection Meets Digital Twin Simulation
The breakthrough will not come from better algorithms applied to the same old data. It will come from fundamentally rethinking how clinical trials collect data — embedding AI-aware protocols into trial design from day one.
Synthetic data generation uses advanced generative AI models (variational autoencoders, GANs, diffusion models) to create realistic, privacy-preserving patient records for three critical applications:
- Pre-trial simulation: Testing thousands of protocol variations — endpoint selections, sample sizes, stratification factors — before recruiting a single real patient
- In-trial augmentation: Supplementing rare subpopulation data to improve statistical power in rare disease trials
- Synthetic control arms: Reducing or eliminating placebo groups, which is both ethically compelling and operationally efficient
Digital twin modeling simulates individual patient biology under different treatments. The mathematical core consists of two interconnected models: one predicting future biomarker states given baseline observations and treatment (an AI-powered PK/PD model at the individual level), and another predicting disease activity indicators from the predicted biological state. Together, they form a patient-specific simulation engine.
The Approach: Data Design Over Algorithm Design
The key insight is that purpose-built, multi-scale biological datasets — not algorithmic sophistication — are what enable models to surpass current limitations. This requires:
- Multi-modal, multi-scale measurement: Coordinated collection across genomics, transcriptomics, proteomics, metabolomics, imaging, and clinical endpoints
- Longitudinal density: Sampling at time points optimized for capturing dynamic treatment responses, not just baseline and endpoint
- Individual-level resolution: Richer per-patient data that supports individual modeling, moving beyond sub-population averages
- Intervention-aware design: Protocols structured so AI models can disentangle treatment, biological response, and clinical outcome
Regulatory acceptance is evolving rapidly. The FDA, EMA, and Swissmedic are developing frameworks for synthetic data and in-silico evidence, emphasizing rigorous validation, documented training data provenance, and continuous performance monitoring aligned with GAMP 5 principles.
How ANG Associates Can Help
ANG Associates brings the rare combination of deep Life Sciences domain expertise, AI strategy capability, and proven IT delivery management needed to operationalize synthetic data and digital twin programs. We help pharmaceutical organizations evaluate synthetic data strategies for clinical trial optimization, build AI governance frameworks for digital twin programs aligned with EU AI Act and Swiss nDSG requirements, and manage the complex multi-vendor IT delivery required to build and validate these platforms. Whether you are a pharma sponsor exploring AI-designed trial protocols or a CRO building next-generation data infrastructure, we bridge the gap between scientific ambition and practical, compliant implementation.